New Generation Smart Drug Delivery Systems for Rheumatoid Arthritis
- 1 April 2023
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 29 (13) , 984-1001
Abstract
Rheumatoid arthritis (RA) is the most common form of the chronic inflammatory autoimmune disease characterized by chronic synovitis, synovial proliferation, and cellular infiltration. Further, it leads to bone erosion, destruction of articular cartilage, intense joint pain, swelling, and a high rate of disability, causing an immense load on human health. If the disease is identified early on, and the patient has continuous and timely treatment, many patients can achieve remission. Although research in RA has made considerable progress, conventional therapies are still the most popular treatment options for most people with RA. But, conventional therapies are hampered by various drawbacks, including higher doses, low solubility and permeability, poor bioavailability, a high level of first-pass metabolism, adaptive treatment tolerance (ATT), and long-term drug use. These drawbacks can result in severe side effects and drug toxicity in patients. Advances in polymer science and the application of nanotechnology in drug delivery systems have provided new possibilities in the treatment of RA by developing new-generation smart drug delivery systems (SDDSs). The shortcomings of non-specific drug distribution and uncontrollable drug release by traditional delivery systems have motivated the creation of next-generation SDDSs. These new smart drug delivery treatment methods have significantly changed the course of RA. Such systems can improve drug delivery by virtue of their multi-functionality and targeting capabilities. The ultimate objective of next-generation SDDSs is to deliver medication at the optimal time with precise dosage and efficiency and specificity to the targeted site (such as cells, tissues, and organs), which can aid patients to adhere better to their therapy. This review highlights and discusses the various next-generation SDDSs along with the conventional treatment options available for RA management.Keywords
Funding Information
- Anusandhan National Research Foundation (CRG/2019/004018)
This publication has 215 references indexed in Scilit:
- Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysisAnnals of the Rheumatic Diseases, 2013
- The problem of choice: current biologic agents and future prospects in RANature Reviews Rheumatology, 2013
- Superparamagnetic Iron Oxide Nanoparticles with Variable Size and an Iron Oxidation State as Prospective Imaging AgentsLangmuir, 2012
- Real-time DNA detection using Pt nanoparticle-decorated reduced graphene oxide field-effect transistorsNanoscale, 2011
- Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: Comparison of prednisolone with budesonideInternational Journal of Pharmaceutics, 2011
- Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re‐treatmentArthritis & Rheumatism, 2010
- Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid ArthritisThe Journal of Rheumatology, 2010
- Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Synthesis and characterization of ultra-small superparamagnetic iron oxide nanoparticles thinly coated with silicaNanotechnology, 2008
- Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Exhibits an Important Intracellular Cleavage Function and Causes Chromosome InstabilityJournal of Biological Chemistry, 2005